Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 9/20 | 0.61 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.61 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.61 |
| ▸ | NPY1R | P25929 | 2/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31151446 | 0.94 | NTSR1 (0.59) | NTSR1NTSR2SORT1AGTR2AGTR1 | |
| SCHEMBL31151670 | 0.93 | NTSR1 (0.60) | NTSR1NTSR2SORT1OPRD1 | |
| SCHEMBL31151473 | 0.92 | OPRD1 (0.61) | AGTR2AGTR1OPRD1OPRM1OPRK1 | |
| SCHEMBL30361896 | 0.92 | NTSR1 (0.61) | NTSR1NTSR2SORT1AGTR2AGTR1 | |
| SCHEMBL29940473 | 0.91 | NTSR1 (0.64) | NTSR1NTSR2SORT1NPY1ROPRD1 | |
| SCHEMBL29414469 | 0.91 | NTSR1 (0.62) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL30361957 | 0.90 | NTSR1 (0.60) | NTSR1NTSR2SORT1AGTR2AGTR1 | |
| SCHEMBL29894426 | 0.89 | NTSR1 (0.63) | NTSR1NTSR2SORT1AGTR2AGTR1 | |
| SCHEMBL30623611 | 0.89 | NTSR1 (0.65) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL30294171 | 0.89 | NTSR1 (0.64) | NTSR1NTSR2SORT1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713002-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | Forssmann, Wolf-Georg (DE) | 2026-03-25 | — | — | EP | claimed |
| EP-4501347-A1 | PEPTIDES FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | claimed |
| EP-4501348-A1 | PEPTIDES FOR USE IN THE IMPROVEMENT OF WELL-BEING | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | claimed |
| WO-2024235986-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | PHARIS BIOTEC GMBH (DE) | 2024-11-21 | — | — | WO | claimed |
| EP-4713002-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | Forssmann, Wolf-Georg (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4501347-A1 | PEPTIDES FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4501348-A1 | PEPTIDES FOR USE IN THE IMPROVEMENT OF WELL-BEING | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024235986-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | PHARIS BIOTEC GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2023099725-A1 | PHARMACEUTICAL PREPARATION CONTAINING A MIXTURE OF A NATRIURETIC PEPTIDE (ANP) AND A PEPTIDIC INHIBITOR OF THE CXCR4 RECEPTOR | PHARIS BIOTEC GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| CN-105530948-B | Peptides having antagonistic activity against natural CXCR4 | 法瑞斯生物技术有限公司 | 2023-05-26 | — | — | CN | disclosed |